Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI) |
| |
| Institution: | 1. Clalit Research Institute, Innovation Division, Clalit Health Services, Ramat Gan, Israel;2. School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel;3. University of Michigan, School of Public Health, Ann Arbor, MI, USA;4. Schneider Children''s Medical Center of Israel, Petach Tikvah, Israel;5. Infectious Diseases and Infection Control Unit, Ha''Emek Medical Center, Afula, Israel;6. Rappaport Faculty of Medicine, Technion, Haifa, Israel;7. Infectious Diseases, Meir Medical Center, Kfar Saba, Israel;8. Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel;9. Pediatric Infectious Disease Unit the Pediatric Division, Soroka University Medical Center, Beer Sheva, Israel;10. Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel;11. Occupational Medicine Clinic, Rabin Medical Center, Petah Tikva, Israel;12. Research Authority, Kaplan Medical Center, Rehovot, Israel;13. The Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel;14. Clalit Central Laboratory, Clalit Health Services, Tel Aviv, Israel;15. Multidisciplinary Laboratory, Schneider Children''s Medical Center of Israel, Petach Tikvah, Israel;p. Clinical Microbiology Laboratory, Ha''Emek Medical Center, Afula, Israel;q. Microbiology Department, Rabin Medical Center, Petah Tikva, Israel;r. Microbiology Department, Kaplan Medical Center, Rehovot, Israel;s. Department of Clinical Laboratories, Meir Medical Center, Kfar Saba, Israel;t. Virology, Soroka University Medical Center, Beer Sheva, Israel;u. Central Virology Laboratory, Chaim Sheba Medical Center, Ministry of Health, Ramat Gan, Israel;v. Department of Epidemiology and Preventive Medicine, Sackler Faculty of Medicine, School of Public Health, Tel Aviv University, Tel Aviv, Israel;w. Laboratory Division, Shamir Medical Center, Zerifin, Israel;x. Software and Information Systems Engineering, Ben Gurion University, Beer Sheva, Israel;y. Department of Biomedical Informatics, Harvard Medical School, Boston, MA, USA;z. Ivan and Francesca Berkowitz Family Living Laboratory at Harvard Medical School, Boston, MA, USA |
| |
| Abstract: | BackgroundMethodologically rigorous studies on Covid-19 vaccine effectiveness (VE) in preventing SARS-CoV-2 infection are critically needed to inform national and global policy on Covid-19 vaccine use. In Israel, healthcare personnel (HCP) were initially prioritized for Covid-19 vaccination, creating an ideal setting to evaluate early real-world VE in a closely monitored population.MethodsWe conducted a prospective study among HCP in 6 hospitals to estimate the effectiveness of the BNT162b2 mRNA Covid-19 vaccine in preventing SARS-CoV-2 infection. Participants filled out weekly symptom questionnaires, provided weekly nasal specimens, and three serology samples – at enrollment, 30 days and 90 days. We estimated VE against PCR-confirmed SARS-CoV-2 infection using the Cox Proportional Hazards model and against a combined PCR/serology endpoint using Fisher’s exact test.ResultsOf the 1567 HCP enrolled between December 27, 2020 and February 15, 2021, 1250 previously uninfected participants were included in the primary analysis; 998 (79.8%) were vaccinated with their first dose prior to or at enrollment, all with Pfizer BNT162b2 mRNA vaccine. There were four PCR-positive events among vaccinated participants, and nine among unvaccinated participants. Adjusted two-dose VE against any PCR-confirmed infection was 94.5% (95% CI: 82.6%-98.2%); adjusted two-dose VE against a combined endpoint of PCR and seroconversion for a 60-day follow-up period was 94.5% (95% CI: 63.0%-99.0%). Five PCR-positive samples from study participants were sequenced; all were alpha variant.ConclusionsOur prospective VE study of HCP in Israel with rigorous weekly surveillance found very high VE for two doses of Pfizer BNT162b2 mRNA vaccine against SARS-CoV-2 infection in recently vaccinated HCP during a period of predominant alpha variant circulation.FundingClalit Health Services. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
